Abbott Laboratories $ABT Shares Bought by Arizona State Retirement System

Posted by Brenda Bartman on Sep 8th, 2026

Arizona State Retirement System lifted its position in Abbott Laboratories (NYSE:ABT – Free Report) by 1.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 483,276 shares of the healthcare product maker’s stock after purchasing an additional 6,774 shares during the quarter. Arizona State Retirement System’s holdings in Abbott Laboratories were worth $43,852,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. California State Teachers Retirement System grew its stake in shares of Abbott Laboratories by 9,127.1% during the 2nd quarter. California State Teachers Retirement System now owns 246,828,861 shares of the healthcare product maker’s stock worth $22,397,251,000 after purchasing an additional 244,153,804 shares during the period. J. Stern & Co. LLP lifted its stake in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Norges Bank acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at $2,938,892,000. Bank of America Corp DE purchased a new stake in Abbott Laboratories during the second quarter worth $1,603,607,000. Finally, Legal & General Group Plc acquired a new stake in Abbott Laboratories during the second quarter valued at $1,082,524,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT traded down $2.67 during trading on Tuesday, reaching $105.66. The company’s stock had a trading volume of 11,397,135 shares, compared to its average volume of 11,627,073. The company has a market cap of $182.82 billion, a price-to-earnings ratio of 34.19, a PEG ratio of 2.01 and a beta of 0.59. The firm has a fifty day simple moving average of $104.74 and a two-hundred day simple moving average of $100.00. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s payout ratio is presently 81.55%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ABT shares. Royal Bank Of Canada restated an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. BTIG Research upped their price target on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research report on Thursday, August 13th. TD Cowen reissued a “buy” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a report on Tuesday. Finally, UBS Group cut their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Get Our Latest Stock Report on Abbott Laboratories

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.